Why Is Belite Bio Stock Soaring Friday?
Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.
Stocks · News reference
Full Transcript: Belite Bio Q2 2026 Earnings Call
Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Belite Bio shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $303 price target.
This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303
Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.